Felbamate Dosage
This dosage information may not include all the information needed to use Felbamate safely and effectively. See additional information for Felbamate.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Epilepsy
Adjunctive therapy: 1200 mg/day in 3-4 divided doses. The daily dose can be increased in 1200 mg increments each week as tolerated to response. Maximum daily dose: 3600 mg.
Monotherapy: 1200 mg/day in 3-4 divided doses. Increase the daily dose in 600 mg increments every two weeks as tolerated to response.
Conversion to monotherapy: 1200 mg/day in 3-4 divided doses. Starting at week 2 the daily dose can be increased in 1200 mg increments weekly. Maximum daily dose: 3600 mg. The dose of concomitant anticonvulsants should be decreased by 1/3 of the original dose at the start of felbamate therapy, when felbamate is increased at week 2, and as clinically necessary.
Usual Pediatric Dose for Lennox-Gastaut Syndrome
>2 years to 14 years with Lennox-Gastaut Syndrome:
Adjunctive therapy: 15 mg/kg/day in 3-4 divided doses. Initial therapy should include reducing the dose of concomitant anticonvulsants by 20%. Increase the dosage of felbamate by 15 mg/kg/day in weekly intervals as tolerated to desired clinical response. Maximum daily dosage: 45 mg/kg/day. Further dosage reductions of concomitant anticonvulsants may be necessary to reduce side effects due to drug interactions.
Liver Dose Adjustments
Felbamate taken by itself or with other prescription and/or nonprescription drugs, can result in a severe, potentially fatal blood abnormality ("aplastic anemia") and/or severe, potentially fatal liver damage.
Precautions
Felbamate taken by itself or with other prescription and/or nonprescription drugs, can result in a severe, potentially fatal blood abnormality ("aplastic anemia") and/or severe, potentially fatal liver damage.
Felbamate should not be used by patients until there has been a complete discussion of the risks and the patient,parent, or guardian has provided written informed consent.
A patient information/consent form is included with the product package insert. The form can also be obtained by contacting the local Wallace representative or calling 609-655-6147.
Other Comments
Felbamate taken by itself or with other prescription and/or nonprescription drugs, can result in a severe, potentially fatal blood abnormality ("aplastic anemia") and/or severe, potentially fatal liver damage.
Felbamate should not be used by patients until there has been a complete discussion of the risks and the patient,parent, or guardian has provided written informed consent.
